You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePlasmin
Accession NumberDB05254
TypeSmall Molecule
GroupsInvestigational
DescriptionPlasmin (also known as Fibrinolysin) is a bovine enzyme derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90,000 daltons. Plasmin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of plasmin; the heavy chain has a molecular weight of approximately 57,000 Da. Plasmin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Plasmin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) plasmin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.
Structure
Thumb
Synonyms
Bovine Fibrinolysin
Bovine Plasmin
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ElaseNot Available
FibrolanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationPlasmin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas
PharmacodynamicsNot Available
Mechanism of actionPlasmin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

local inactivation

Route of eliminationNot Available
Half lifeAlmost completely inactivated after 24 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US2624691 No1953-01-061980-01-06Us
US3136703 No1964-06-091981-06-09Us
US3234106 No1966-02-081983-02-08Us
Properties
StateLiquid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis ReferenceNot Available
General References
  1. Birk Y, Khalef S, Jibson MD: Purification and properties of protease F, a bacterial enzyme with chymotrypsin and elastase specificities. Arch Biochem Biophys. 1983 Sep;225(2):451-7. [PubMed:6226244 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabPlasmin may increase the anticoagulant activities of Abciximab.
AcenocoumarolPlasmin may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Plasmin.
AlprostadilAlprostadil may increase the anticoagulant activities of Plasmin.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Plasmin.
AnagrelideAnagrelide may increase the anticoagulant activities of Plasmin.
AncrodPlasmin may increase the anticoagulant activities of Ancrod.
Antithrombin III humanPlasmin may increase the anticoagulant activities of Antithrombin III human.
ApixabanPlasmin may increase the anticoagulant activities of Apixaban.
AprotininThe therapeutic efficacy of Plasmin can be decreased when used in combination with Aprotinin.
ArdeparinPlasmin may increase the anticoagulant activities of Ardeparin.
ArgatrobanPlasmin may increase the anticoagulant activities of Argatroban.
AzelastineAzelastine may increase the anticoagulant activities of Plasmin.
BecaplerminPlasmin may increase the anticoagulant activities of Becaplermin.
BeraprostBeraprost may increase the anticoagulant activities of Plasmin.
BivalirudinPlasmin may increase the anticoagulant activities of Bivalirudin.
CangrelorCangrelor may increase the anticoagulant activities of Plasmin.
CertoparinPlasmin may increase the anticoagulant activities of Certoparin.
CilostazolCilostazol may increase the anticoagulant activities of Plasmin.
Citric AcidPlasmin may increase the anticoagulant activities of Citric Acid.
ClopidogrelClopidogrel may increase the anticoagulant activities of Plasmin.
Dabigatran etexilatePlasmin may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinPlasmin may increase the anticoagulant activities of Dalteparin.
DanaparoidPlasmin may increase the anticoagulant activities of Danaparoid.
DefibrotideDefibrotide may increase the anticoagulant activities of Plasmin.
DesirudinPlasmin may increase the anticoagulant activities of Desirudin.
DextranPlasmin may increase the anticoagulant activities of Dextran.
Dextran 40Plasmin may increase the anticoagulant activities of Dextran 40.
Dextran 70Plasmin may increase the anticoagulant activities of Dextran 70.
Dextran 75Plasmin may increase the anticoagulant activities of Dextran 75.
DicoumarolPlasmin may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Plasmin.
DipyridamoleDipyridamole may increase the anticoagulant activities of Plasmin.
Edetic AcidPlasmin may increase the anticoagulant activities of Edetic Acid.
EdoxabanPlasmin may increase the anticoagulant activities of Edoxaban.
EnoxaparinPlasmin may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the anticoagulant activities of Plasmin.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Plasmin.
EpoprostenolThe risk or severity of adverse effects can be increased when Plasmin is combined with Epoprostenol.
EptifibatideEptifibatide may increase the anticoagulant activities of Plasmin.
Ethyl biscoumacetatePlasmin may increase the anticoagulant activities of Ethyl biscoumacetate.
Fondaparinux sodiumPlasmin may increase the anticoagulant activities of Fondaparinux sodium.
HeparinPlasmin may increase the anticoagulant activities of Heparin.
HirulogPlasmin may increase the anticoagulant activities of Hirulog.
IbudilastIbudilast may increase the anticoagulant activities of Plasmin.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Plasmin.
IfenprodilIfenprodil may increase the anticoagulant activities of Plasmin.
IloprostIloprost may increase the anticoagulant activities of Plasmin.
IloprostThe risk or severity of adverse effects can be increased when Plasmin is combined with Iloprost.
LepirudinPlasmin may increase the anticoagulant activities of Lepirudin.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Plasmin.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Plasmin.
MilrinoneMilrinone may increase the anticoagulant activities of Plasmin.
NadroparinPlasmin may increase the anticoagulant activities of Nadroparin.
NCX 4016NCX 4016 may increase the anticoagulant activities of Plasmin.
NimesulideNimesulide may increase the anticoagulant activities of Plasmin.
OtamixabanPlasmin may increase the anticoagulant activities of Otamixaban.
Pentosan PolysulfatePlasmin may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Plasmin.
PhenindionePlasmin may increase the anticoagulant activities of Phenindione.
PhenprocoumonPlasmin may increase the anticoagulant activities of Phenprocoumon.
PrasugrelPrasugrel may increase the anticoagulant activities of Plasmin.
Protein CPlasmin may increase the anticoagulant activities of Protein C.
ProtocatechualdehydePlasmin may increase the anticoagulant activities of Protocatechualdehyde.
ResveratrolResveratrol may increase the anticoagulant activities of Plasmin.
ReviparinPlasmin may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Plasmin.
RivaroxabanPlasmin may increase the anticoagulant activities of Rivaroxaban.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Plasmin.
SCH-530348SCH-530348 may increase the anticoagulant activities of Plasmin.
SevofluraneSevoflurane may increase the anticoagulant activities of Plasmin.
SRT501SRT501 may increase the anticoagulant activities of Plasmin.
SulodexidePlasmin may increase the anticoagulant activities of Sulodexide.
TesmilifeneTesmilifene may increase the anticoagulant activities of Plasmin.
TiclopidineTiclopidine may increase the anticoagulant activities of Plasmin.
TirofibanTirofiban may increase the anticoagulant activities of Plasmin.
TranilastTranilast may increase the anticoagulant activities of Plasmin.
TrapidilTrapidil may increase the anticoagulant activities of Plasmin.
TreprostinilThe risk or severity of adverse effects can be increased when Plasmin is combined with Treprostinil.
TriflusalTriflusal may increase the anticoagulant activities of Plasmin.
VorapaxarVorapaxar may increase the anticoagulant activities of Plasmin.
WarfarinPlasmin may increase the anticoagulant activities of Warfarin.
XimelagatranPlasmin may increase the anticoagulant activities of Ximelagatran.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.
Gene Name:
SERPINE1
Uniprot ID:
P05121
Molecular Weight:
45059.695 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Gene Name:
PLAU
Uniprot ID:
P00749
Molecular Weight:
48507.09 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:09 / Updated on August 17, 2016 12:24